Počet záznamov: 1
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid celIs surface antigens [I] CD19, CD20 and CD52).
SYS 0148611 LBL 00000naa^^22^^^^^^^^450 005 20201207142907.3 100 $a 20180815d2018 m y0sloy0103 ba 101 0-
$a eng 102 $a SK 200 1-
$a ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid celIs surface antigens [I] CD19, CD20 and CD52). $f Drgoňa L. ... [et al.] 305 $a Clinical microbiology and infections, Jun 24, Suppl.2 (2018), S71-S82 463 -1
$1 001 sllk_un_cat*0147827 $1 011 $a 1336-8176 $1 200 1 $a Onkológia $v Roč. 13, č. 3 (2018), s. 222 $1 210 $a Bratislava $c SOLEN $d 2018 $1 215 $a s. 157-226 606 1-
$3 sllk_un_auth*d009894 $a infekcie oportúnne $x etiológia $x prevencia a kontrola $2 mesh 606 1-
$3 sllk_un_auth*d058990 $a terapia molekulárne cielená $x účinky nežiaduce $2 mesh 606 1-
$3 sllk_un_auth*d001691 $a terapia biologická $x účinky nežiaduce $2 mesh 606 2-
$3 sllk_un_auth*d012449 $a bezpečnosť $2 mesh 606 2-
$3 sllk_un_auth*d000911 $a protilátky monoklonálne $2 mesh 606 2-
$3 sllk_un_auth*d018941 $a antigény CD19 $2 mesh 606 2-
$3 sllk_un_auth*d018951 $a antigény CD20 $2 mesh 606 2-
$3 sllk_un_auth*d000074301 $a antigén CD52 $x antagonisty a inhibítory $2 mesh 606 2-
$3 sllk_un_auth*d000074323 $a alemtuzumab $2 mesh 610 2-
$a anti-CD19 610 2-
$a blinatumomab 610 2-
$a inebilizumab 610 2-
$a anti-CD20 701 -1
$3 sllk_un_auth*p0063373 $a Drgoňa $b Ľuboš $p Odd. klinickej hematológie a transfuziológie, Národný onkologický ústav, Katedra klinickej onkológie SZU, Bratislava $4 100 711 02
$3 sllk_un_auth*0012742 $a Redakcia Onkológia $4 010 801 -0
$a SK $b BA006 $c 20180815 $g AACR2
Počet záznamov: 1